Several brokerages have updated their recommendations and price targets on shares of Henry Schein (NASDAQ: HSIC) in the last few weeks:

  • 8/9/2017 – Henry Schein was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Henry Schein exited second-quarter 2017 on a solid note with earnings and sales beating the Zacks Consensus Estimate. Apart from balanced growth across all its operating segments, Henry Schein's share gains in both the U.S. and overseas markets raise optimism. We are also positive about the company opening a National Distribution Service Center to strengthen its presence in central Ohio. On the flip side, over the last three months, the company has underperformed the broader industry. Also, despite the better-than-expected earnings, we are disappointed with the company’s unchanged EPS guidance for 2017. Meanwhile, Henry Schein’s venture in digital dentistry through DENTSPLY SIRONA deal may intensify its already weak operating margin scenario on escalating education and training expenses. Also, foreign currency fluctuations continued to mar the company’s financials.”
  • 8/7/2017 – Henry Schein was upgraded by analysts at Northcoast Research from a “neutral” rating to a “buy” rating. They now have a $218.00 price target on the stock.
  • 8/2/2017 – Henry Schein was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/21/2017 – Henry Schein had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $177.00 price target on the stock.
  • 7/13/2017 – Henry Schein had its “hold” rating reaffirmed by analysts at Credit Suisse Group. They now have a $160.00 price target on the stock.
  • 7/6/2017 – Henry Schein had its “hold” rating reaffirmed by analysts at Stifel Nicolaus.
  • 6/23/2017 – Henry Schein was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “In the past three months, Henry Schein has consistently outperformed the S&P 500 Market at large with respect to share price movement. Apart from balanced segmental growth across all its operating segments, the company’s share gains in both the U.S. and overseas markets raise optimism. Management is also upbeat about several strategic tie ups made during the reported quarter. We are also positive about Henry Schein’s buyout of Marrodent and SAS which have the potential to capture the bountiful dental market opportunities. On the flip side despite a strong quarterly show last time, the company’s unchanged EPS guidance for 2017 is uninspiring. Meanwhile, Henry Schein’s venture in digital dentistry through Dentsply Sirona deal may intensify its already weak operating margin scenario on escalating education and training expenses. Also, foreign currency fluctuations continued to mar the company’s financials.”
  • 6/16/2017 – Henry Schein was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $206.00 price target on the stock. According to Zacks, “In the past three months, Henry Schein has consistently outperformed the S&P 500 Market at large with respect to share price movement. Apart from balanced segmental growth across all its operating segments, the company’s share gains in both the U.S. and overseas markets raise optimism. Management is also upbeat about several strategic tie ups made during the reported quarter. We are also positive about Henry Schein’s buyout of Marrodent and SAS which have the potential to capture the bountiful dental market opportunities. On the flip side despite a strong quarterly show last time, the company’s unchanged EPS guidance for 2017 is uninspiring. Meanwhile, Henry Schein’s venture in digital dentistry through Dentsply Sirona deal may intensify its already weak operating margin scenario on escalating education and training expenses. Also, foreign currency fluctuations continued to mar the company’s financials.”
  • 6/15/2017 – Henry Schein was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “In the past three months, Henry Schein has consistently outperformed the S&P 500 Market at large with respect to share price movement. Apart from balanced segmental growth across all its operating segments, the company’s share gains in both the U.S. and overseas markets raise optimism. Management is also upbeat about several strategic tie ups made during the reported quarter. We are also positive about Henry Schein’s buyout of Marrodent and SAS which have the potential to capture the bountiful dental market opportunities. On the flip side despite a strong quarterly show last time, the company’s unchanged EPS guidance for 2017 is uninspiring. Meanwhile, Henry Schein’s venture in digital dentistry through Dentsply Sirona deal may intensify its already weak operating margin scenario on escalating education and training expenses. Also, foreign currency fluctuations continued to mar the company’s financials.”
  • 6/12/2017 – Henry Schein is now covered by analysts at Piper Jaffray Companies. They set a “neutral” rating and a $200.00 price target on the stock.

Henry Schein, Inc. (HSIC) opened at 167.32 on Friday. The stock has a market cap of $13.25 billion, a price-to-earnings ratio of 24.45 and a beta of 1.09. Henry Schein, Inc. has a one year low of $146.23 and a one year high of $186.99. The firm’s 50 day moving average price is $181.94 and its 200 day moving average price is $175.01.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $1.75 EPS for the quarter, topping analysts’ consensus estimates of $1.73 by $0.02. The firm had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The firm’s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.64 EPS. Equities analysts forecast that Henry Schein, Inc. will post $7.28 earnings per share for the current year.

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Receive News & Ratings for Henry Schein Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.